Aptadel Therapeutics

Startup

Aptadel Therapeutics is a pre-clinical stage drug development biotech company exploiting RNA Aptamer technologies for the treatment of cancer. Its Aptamer technology is a delivery tool platform for different therapeutic agents (siRNA, miRNA, chemotherapeutic drugs, small molecules) that can be used in several indications. Aptadel's lead compound, ADEL-101, is an aptamer-small interfering RNA (siRNA) conjugate designed for the treatment of Ewing Sarcoma (ES), a childhood cancer with a high mortality rate. ADEL-101 benefits from a dual mode of action that allows high-specificity targeting of the primary tumor and reduction of metastatic processes.

website